9.2 Controlled Substance Safety & Opioid Stewardship

9.2 Controlled Substance Safety & Opioid Stewardship

Blueprint focus: ONCC Domain II.O — Controlled substance safety. This blueprint item is separate from pain management itself. It asks whether the nurse practitioner can prescribe opioids safely and legally while still treating cancer pain adequately.

---

The Central Tension

Undertreated cancer pain is a documented harm, and so is opioid-related overdose. The regulatory environment built after the opioid crisis was largely designed around chronic non-cancer pain, and applying it uncritically to a patient with bone metastases causes real suffering. The answer is neither reflexive prescribing nor reflexive restriction; it is stewardship — the right drug, the right dose, the right monitoring, and documentation that would withstand review.

The 2022 CDC clinical practice guideline explicitly states that its dose thresholds are not intended as inflexible limits and that patients with cancer-related pain, sickle cell disease, and palliative or end-of-life care warrant individualized management. Quoting an arbitrary milligram ceiling at a patient with progressive malignancy is a misapplication of that guidance.

---

Universal Precautions

Apply the same structured approach to every patient started on an opioid. This is both safer and more equitable, since clinician "gut feeling" about who might misuse medication tracks race and socioeconomic status far more than it tracks actual risk.

1. Establish and document the pain diagnosis and the mechanism.
2. Assess risk with a validated tool before the first prescription.
3. Check the prescription drug monitoring program (PDMP) database.
4. Obtain a baseline urine drug test.
5. Set explicit treatment goals — a function target, not only a numeric pain score.
6. Use a treatment agreement describing one prescriber, one pharmacy, refill procedure, storage, and the conditions under which the plan changes.
7. Re-evaluate at defined intervals using the four A's: Analgesia, Activities of daily living, Adverse effects, and Aberrant behaviors.
8. Document the reasoning, not just the prescription.

Risk stratification tools

• Opioid Risk Tool (ORT) — brief; scores personal and family history of substance use, age, history of preadolescent sexual abuse, and psychological disease.
• SOAPP-R (Screener and Opioid Assessment for Patients with Pain, Revised) — 24 items, predicts aberrant medication-related behavior.
• COMM (Current Opioid Misuse Measure) — designed for ongoing monitoring rather than initial screening.

A high score does not withhold analgesia. It changes structure: shorter prescription intervals, more frequent visits, pill counts, more frequent urine testing, single-pharmacy dispensing, and addiction medicine co-management.

---

Terminology the Exam Tests

Confusing tolerance or physical dependence with addiction is the single commonest conceptual error in opioid prescribing, and it drives inappropriate under-dosing of patients with advanced cancer.

---

Monitoring Tools in Practice

PDMP. Query before initiating and at defined intervals, per state law. Look for multiple prescribers, multiple pharmacies, overlapping benzodiazepine prescriptions, and early fills. A concerning pattern opens a conversation; it does not by itself justify abrupt discontinuation.

Urine drug testing. Two important interpretive points:

• A negative result for the prescribed opioid may mean diversion, non-adherence, or an assay limitation. Standard immunoassay opiate screens detect morphine and codeine but frequently miss oxycodone, methadone, fentanyl, and buprenorphine, all of which require specific assays or confirmatory mass spectrometry.
• Unexpected positives must be interpreted against metabolic pathways: codeine metabolizes to morphine, hydrocodone to hydromorphone, and heroin to 6-monoacetylmorphine and then morphine. A morphine-positive result in a patient prescribed codeine is expected, not evidence of misuse.

Discuss discrepancies with the patient before drawing conclusions, and send confirmatory testing.

Naloxone co-prescribing. Offer take-home naloxone and train the patient and household when any of the following apply: a high daily morphine milligram equivalent, concurrent benzodiazepine or other sedative, history of overdose or substance use disorder, sleep-disordered breathing, significant renal or hepatic impairment, or an older adult living alone.

Storage and disposal. Teach patients to store opioids in a locked box, never in an unsecured medicine cabinet or purse, and never to share. For disposal, direct patients to DEA take-back sites or pharmacy kiosks. Fentanyl patches are the notable exception to disposal caution: because a used patch retains enough drug to kill a child or pet, patients are instructed to fold the adhesive sides together and dispose of it as directed by the label, which for fentanyl explicitly permits flushing.

---

Federal Prescribing Rules

• Schedule II substances (morphine, oxycodone, hydromorphone, fentanyl, methadone, methylphenidate): no refills are permitted. Each dispensing requires a separate prescription. A prescriber may, however, issue multiple prescriptions on the same day authorizing up to a 90-day total supply, provided each prescription bears the earliest date on which it may be filled and this is permitted by state law.
• Schedules III and IV: up to five refills within 6 months of the issue date.
• Electronic prescribing of controlled substances is required for Medicare Part D and increasingly by state law.
• The DATA-2000 waiver ("X waiver") was eliminated by the Consolidated Appropriations Act of 2023, so any clinician with a standard DEA registration may now prescribe buprenorphine for opioid use disorder — relevant when a cancer patient also needs treatment for a substance use disorder.
• State law may be more restrictive than federal law on quantity limits, mandatory PDMP checks, and days-supply caps for opioid-naive patients.

---

Cancer Pain in Patients With Substance Use Disorder

These patients have cancer pain and deserve treatment for it.

• Do not withhold opioids because of a substance use history. Untreated pain drives relapse.
• Involve addiction medicine and palliative care early and co-manage.
• Use structure: short prescription intervals, weekly or biweekly dispensing, pill counts, single pharmacy, more frequent urine testing.
• Prefer long-acting scheduled dosing over large as-needed quantities, which reduces the reinforcing peak-and-trough pattern.
• Patients on buprenorphine or methadone maintenance can and should continue it. Buprenorphine is generally continued through cancer treatment, with additional full-agonist opioid titrated for acute pain; abruptly stopping maintenance therapy destabilizes both the pain and the addiction.
• Maximize non-opioid and interventional options: adjuvants, radiation to painful bone metastases, nerve blocks, and intrathecal pumps.
• Document objectively and without pejorative language. "Requested an early refill and reported that the dose lasts 5 hours" is useful; "drug-seeking" is not.